Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as ...

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...

Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. This week, the medicine, first approved in 2009, was listed as discontinued on the ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who plans to retire in June next year.

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...

Ultratech Cement Q3 Results 2025 Highlights: Ultratech Cement announced its Q3 results today. The Aditya Birla Group cement maker reported a 17% year-on-year (YoY) decline in its net profit in the ...